such as hyperactivity. EndeavorRx should be considered for use as part of a therapeutic program that may include clinician-directed therapy, medication and/or educational programs, which further
address symptoms of the disorder. EndeavorRx is available by prescription only. It is not intended to be used as a stand-alone therapeutic and is not a substitution for a childs medication. The most common side effect observed in children in
EndeavorRxs clinical trials was a feeling of frustration, as the game can be quite challenging at times. No serious adverse events were associated with its use. EndeavorRx is recommended to be used for approximately 25 minutes a day, 5 days a
week, over initially at least 4 consecutive weeks, or as recommended by your childs health care provider. To learn more about EndeavorRx, please visit EndeavorRx.com.
About Akili
Akili is pioneering the development of
cognitive treatments through game-changing technologies. Akilis approach of leveraging technologies designed to directly target the brain establishes a new category of medicine medicine that is validated through clinical trials like a
drug or medical device, but experienced like entertainment. Akilis platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain, informed by decades of research and validated through
rigorous clinical programs. Driven by Akilis belief that effective medicine can also be fun and engaging, Akilis products are delivered through captivating action video game experiences. For more information, please visit
www.akiliinteractive.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These
forward-looking statements generally are identified by the words believe, project, expect, anticipate, estimate, intend, strategy, future,
opportunity, plan, may, should, will, would, will be, will continue, will likely result, and similar expressions. Forward-looking statements
are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties.
These forward-looking statements include, without limitation, statements in this press release related to: the ability of EndeavorOTC to improve attention
function, ADHD symptoms and quality of life in adults with ADHD and the growing need for ADHD treatment and non-pharmacological options. Any forward-looking statements in this press release are based on
managements current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without limitation, risks and uncertainties related to: the risk that prior results, such as signals of efficacy or safety observed from clinical trials will not continue or be repeated in
EndeavorOTC or our ongoing or planned clinical trials, or will be insufficient to support regulatory submissions or support or maintain marketing approval in the United States or other jurisdictions, or that long-term adverse safety findings may be
discovered; the risk that our products will not be further developed or commercialized successfully; the timing and results expected from our and our partners clinical trials and our reliance on third parties for certain aspects of our
business; our ability to accurately estimate expenses, capital requirements, and needs for additional financing; and other risks identified in our current filings and any subsequent filings made with the Securities and Exchange Commission (SEC). We
caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof and should not be relied upon as representing the companys views as of any